Roche c501/e411 Autoanalyzer for CTSA Core Resources at Penn and CHOP

描述（由申请人提供）：临床和转化科学是宾夕法尼亚大学（Penn）和费城儿童医院（CHOP）的主要重点。事实上，宾夕法尼亚大学/CHOP CTSA通过CTSA的学术基地——转化医学和治疗学研究所（ITMAT），促进了在转化研究方面的主要机构投资。ITMAT/CTSA的主要转型任务是通过转化核心实验室（TCL）为研究样品处理、存储和分析提供经济高效的服务。TCL的一项关键服务是专门针对临床病理学无法满足的研究需求的自动分析仪，包括小样本量的批量分析和最佳多路复用。TCL使用罗氏日立912自动分析仪进行以研究为重点的生化分析，然而，日立912现在是一个老化的平台，罗氏在今年年底后将不再支持。在这份共享仪器拨款提案中，我们寻求用罗氏Cobas c501/e411生化/免疫化学自分析仪取代该平台。该分析仪将(a)在使用类似试剂的同时增加容量（从而确保正在进行的项目的连续性），(b)扩展分析仪服务，包括对该研究界至关重要的更广泛的多路复用选项（有限的样本资源是常态），以及(c)满足对这些服务日益增长的需求。我们提出了五个主要的用户项目，以说明这些服务对宾夕法尼亚大学/CHOP及其以外的临床和转化研究的独特重要性和范围-项目涵盖儿科到成人研究，K-23到U01奖，包括机械临床试验，社区转化研究和流行病学研究。然而，我们强调，该分析仪将被超过40名美国国立卫生研究院资助的研究人员用于临床病理学或其他方法无法适当满足的专业研究应用。提供以研究为导向、高质量、可获得且具有成本效益的自动分析仪服务对于宾夕法尼亚大学/CHOP及其ctsa相关合作伙伴的生物医学研究目标以及NIH在全国范围内加强临床和转化研究的更大使命至关重要。

DESCRIPTION (provided by applicant): Clinical and translational science is a major focus for the University of Pennsylvania (Penn) and Children's' Hospital of Philadelphia (CHOP). Indeed, the Penn/CHOP CTSA has catalyzed major institutional investments in translational research through the Institute of Translational Medicine and Therapeutics (ITMAT), the academic home of the CTSA. A major transformational mission of ITMAT/CTSA is to provide cost-effective and efficient services for research sample processing, storage, and assaying through the Translational Core Laboratories (TCL). A key TCL service has been autoanalyzers exclusively focused on research needs that cannot be met by Clinical Pathology including batch analysis of small sample volumes and optimal multiplexing. The TCL has used a Roche Hitachi 912 autoanalyzer for research-focused biochemical analyses - however, the Hitachi 912 is now an aging platform and will not be supported by Roche after the end of this calendar year. In this Shared Instrumentation Grant proposal, we seek to replace this platform with a Roche Cobas c501/e411 biochemical/immunochemical autoananlyzer. This analyzer will (a) increase capacity while using similar reagents (thus ensuring continuity for ongoing projects), (b) extend analyzer services to include a much broader array of multiplexing options which is critical to this research community (limited sample resources is the norm), and (c) meet an increasing demand for these service. We present five major users projects to illustrate the unique importance and reach of these services to clinical and translational research across Penn/CHOP and beyond - projects span pediatric to adult research, K-23 to U01 awards, and include mechanistic clinical trials, community translational research, and epidemiological studies. We emphasize, however, that this analyzer will be used by over 40 NIH-funded investigators for specialized research applications that cannot appropriately be met by Clinical Pathology or by alternative methodologies. Provision of research oriented, high-quality, accessible and cost-effective autoanalyzer services is critical to the biomedical research goals of Penn/CHOP and their CTSA-related partners as well as to the larger NIH mission to enhance clinical and translational research nationally.